ArticleJournal of perinatology : official journal of the California Perinatal Association2022
Rates of substance and polysubstance use through universal maternal testing at the time of delivery.
Article in Journal of perinatology : official journal of the California Perinatal Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Disparities in Healthcare Providers' Substance Use Detection Practices for Pregnant Patients.Journal of racial and ethnic health disparities · 2026Article
- Utilization of health and supportive services amongst children with prenatal opioid exposure: a mixed methods and community-initiated analysis.BMC health services research · 2026Article
- Choline supplementation partially reverses prefrontal neurochemical deficits induced by perinatal opioid exposure.Scientific reports · 2026Article
- Tobacco and cannabis use among pregnant women with prenatal opioid use.Addictive behaviors · 2025Article
- Trends in Prenatal Polysubstance Exposure.Families in society : the journal of contemporary human services · 2025Article
- Prefrontal cortical microglial transcriptome relates to mouse offspring executive function deficits after perinatal opioid exposure in a sex-dependent manner.Brain, behavior, and immunity · 2025Article
- Factors Associated with Positive Toxicology at Delivery: Insights From the University of Maryland Medical System.Maternal and child health journal · 2025Article
- Evaluating maternal drug use disparities, risk factors and outcomes in Northeast Arkansas: a pre, during, and post-COVID-19 pandemic analysis.BMC public health · 2025Article
- Methadone directly impairs central nervous system cells in vitro.Scientific reports · 2024Article
- Advances in animal models of prenatal opioid exposure.Trends in neurosciences · 2024Review
- Prenatal Opioid Exposure and Risk for Adverse Brain and Motor Outcomes in Infants Born Premature.The Journal of pediatrics · 2024Article
- Prenatal tobacco smoke exposure and risk for cognitive delays in infants born very premature.Scientific reports · 2024Article
- Perinatal morphine but not buprenorphine affects gestational and offspring neurobehavioral outcomes in mice.Neurotoxicology · 2023Article
- Developmental implications of prenatal opioid exposure among school-aged children: a mixed methods and community-initiated analysis.BMC public health · 2023Article
- Prenatal tobacco smoke exposure and risk of brain abnormalities on magnetic resonance imaging at term in infants born very preterm.American journal of obstetrics & gynecology MFM · 2023Article
- Improving translational relevance: The need for combined exposure models for studying prenatal adversity.Brain, behavior, & immunity - health · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveTo report substance and polysubstance use at the time of delivery. STUDY
designA cross-sectional study was performed on mothers consented for universal drug testing (99%) during hospital admission at six delivery hospitals in Cincinnati, Ohio. Mass spectrometry urinalysis detected positivity rates of 46 substances. Rates of positive drug tests for individual and common co-occurring substances measured were reported.
results2531 maternal samples were tested (88%) and 33% contained cotinine, 11.3% THC, 7.2% opioids, 3.8% cocaine, and 1.9% methamphetamines. Polysubstance use prevalence was as high as 15%. Among mothers testing positive for methadone or buprenorphine, 93% also tested positive for cotinine and 39% tested positive for a third substance in addition to cotinine.
conclusionsSubstance use at delivery is more prevalent than previously reported. Many mothers testing positive for opioids also test positive for other substances, which may increase overdose risk and exacerbate neonatal opioid withdrawal syndrome (NOWS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.